UK-based pharmaceutical company ViiV Healthcare has reported results from a trial of Dovato, a two-drug regimen consisting of ...

GlaxoSmithKline’s HIV joint venture ViiV Healthcare could mount a challenge ... injected every eight weeks in a formulation that the company hopes will be more appealing than Gilead’s daily ...

Since 1999, Feb. 7 has marked National Black HIV/AIDS Awareness Day, drawing attention to the disproportionate impact of HIV on Black communities. | Since 1999, Feb. 7 has marked National Black ...

The Navigating HIV video series aims to role model what open and honest conversations between patients and HCPs can look like.

The European Commission (EC) has authorised the use of ViiV Healthcare’s Vocabria (cabotegravir long-acting injections) plus ...

ViiV Healthcare and Johnson & Johnson have been ... HIV and more than 100,000 new cases diagnosed every year, and the company said this morning that expanding treatment options is “critical ...

European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria plus Rekambys for HIV treatment in adolescents: London, UK Saturday, February 1, 2025, 11:00 Hrs ...

A specialist HIV company, ViiV Healthcare is majority-owned by GSK while Shionogi and Pfizer are shareholders. "ViiV Healthcare and J&J’s adolescent HIV-1 combo gains EC authorisation" was ...

London, 31 January 2025 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced that the European Commission has ...

London: GSK plc has announced that ViiV Healthcare, the global HIV company majority owned by GSK, with Pfizer and Shionogi as ...